Addleshaw Goddard advises Aleos Capital on the first closing of Aleos Fund I

Addleshaw Goddard has advised Aleos Capital on the first closing of its fund, Aleos Fund I, which has reached investment commitments exceeding 150 million euros, thus surpassing the initially planned target size.

This vehicle aims to invest in companies in the biosciences sector, with a specific focus on opportunities related to health and well‑being, sustainable nutrition, and climate and environmental solutions. To this end, it plans to invest in companies with significant growth potential, focusing on Spain and Portugal.

Aleos Capital expects to make its first investment in a high‑growth company in the biosciences sector before completing the final closing of the fund, scheduled for the end of this year and which has a hard cap of 240 million euros.

The Addleshaw Goddard team that advised Aleos Capital was led by partner and head of the Funds team, Isabel Rodríguez, with the collaboration of senior associate Enrique Torné and associate Nemesio Fernández.